Skip to main content

Month: June 2020

Saia to Announce Second Quarter 2020 Results on July 29, 2020

JOHNS CREEK, Ga., June 30, 2020 (GLOBE NEWSWIRE) — Saia, Inc. (NASDAQ: SAIA), a leading transportation provider offering multi-regional less-than-truckload (LTL), non-asset truckload, expedited and logistics services, announced that it will release its quarterly financial results before the market opens on Wednesday, July 29. Saia management will host a conference call to discuss the results later that morning at 10:00 a.m. Eastern Time.To participate in the call, please dial 800-367-2403 or 334-777-6978 referencing conference ID #1964358. Callers should dial in five to ten minutes in advance of the conference call. This call will be webcast live via the company website at www.saiacorp.com. A replay of the call will be offered two hours after the completion of the call through August 26 at 1:00 p.m. Eastern Time. The replay will...

Continue reading

Brampton Brick Limited Announces Election of Directors

BRAMPTON, Ontario, June 30, 2020 (GLOBE NEWSWIRE) — Brampton Brick Limited (the “Corporation”) (TSX: BBL.A) is pleased to announce that all of the director nominees listed in the management information circular dated May 11, 2020 (the “Circular”) for the annual general and special meeting of shareholders (the “Meeting”) held June 30, 2020 have been elected as directors of the Corporation.Voting results by way of ballot for each of the individual directors are presented below:The proxy voting results for all matters voted on at the Meeting will be filed on SEDAR at www.sedar.com.About the CorporationBrampton Brick Limited is Canada’s second largest manufacturer of clay brick, serving markets in Ontario, Quebec and the Northeast and Midwestern United States from its brick manufacturing plants located in Brampton, Ontario and Farmersburg,...

Continue reading

Mercury Systems Receives $25M Integrated Subsystems Order for Electronic Support Application

ANDOVER, Mass., June 30, 2020 (GLOBE NEWSWIRE) — Mercury Systems, Inc. (NASDAQ: MRCY, www.mrcy.com), a leader in trusted, secure mission-critical technologies for aerospace and defense, announced it received a $25 million follow-on order from a leading defense prime contractor for integrated radio frequency (RF) and digital subsystems for an advanced naval electronic support application. The order was booked in the Company’s fiscal 2020 fourth quarter and is expected to be shipped over the next several quarters.“Receiving this follow-on order demonstrates our focus on developing the most advanced RF conversion and digital signal processing technologies and making them profoundly more accessible to the defense industry,” said Neal Austin, Vice President and General Manager of Mercury’s Embedded Sensor Processing group. “As...

Continue reading

Fusion Acquisition Corp. Announces Closing of $350,000,000 Million Initial Public Offering

NEW YORK, June 30, 2020 (GLOBE NEWSWIRE) — Fusion Acquisition Corp (NYSE: FUSE.U) (the “Company”) today announced that it closed its initial public offering of 35,000,000 units, including 4,500,000 units issued pursuant to the exercise by the underwriters of their over-allotment option. The offering was priced at $10.00 per unit, resulting in gross proceeds of $350,000,000.The units are listed on the New York Stock Exchange (“NYSE”) and commenced trading under the ticker symbol “FUSE.U” on June 26, 2020. Each unit consists of one share of Class A common stock and one-half of one redeemable warrant, with each whole warrant exercisable to purchase one share of Class A common stock at a price of $11.50 per share. Only whole warrants will be exercisable. Once the securities comprising the units begin separate trading, the shares of...

Continue reading

Sun BioPharma, Inc. Receives FDA Fast Track Designation for SBP-101

MINNEAPOLIS, June 30, 2020 (GLOBE NEWSWIRE) — Sun BioPharma, Inc. (OTCQB: SNBP), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with pancreatic cancer, today announced receipt of Fast Track Designation from the U.S. Food and Drug Administration (FDA) for its lead product, SBP-101, being developed for first-line treatment of patients with metastatic pancreatic ductal adenocarcinoma (PDA) when administered in combination with gemcitabine and nab-paclitaxel.One of FDA’s Expedited Programs for Serious Conditions, Fast Track is a process designed to facilitate the development and potentially expedite the review of drugs intended to treat serious conditions and address unmet medical needs. Programs with Fast Track Designation may benefit from more frequent meetings with and...

Continue reading

Manitou Gold Announces Appointment of New Director, Completes Property Acquisition and Share Issuances 

SUDBURY, Ontario, June 30, 2020 (GLOBE NEWSWIRE) — Manitou Gold Inc. (TSXV: MTU) (the “Company” or “Manitou”) is pleased to announce that effective June 30, 2020, it has appointed Peter MacPhail as a new director of the Corporation. Mr. MacPhail has more than 35 years of operational mining experience in Canada, Mexico and Australia. Mr. MacPhail is the Chief Operating Officer of Alamos Gold Inc (“Alamos”), a position he has held since 2015. Previously, he was Chief Operating Officer of AuRico Gold and served in the same capacity at Northgate Minerals. Prior to Northgate, Mr. MacPhail held increasingly senior roles at Noranda, Teck Resources, Homestake Mining and Barrick Gold. He holds a Bachelor of Applied Science degree in Mineral Engineering from the University of Toronto and is a licensed Professional Engineer in Ontario.“I am...

Continue reading

G1 Therapeutics and Boehringer Ingelheim Announce Co-Promotion Agreement for Trilaciclib in Small Cell Lung Cancer in the United States and Puerto Rico

– Partnership leverages Boehringer Ingelheim’s oncology expertise to lead trilaciclib SCLC launch sales engagements– G1 to retain full development and commercialization rights and book revenue for trilaciclib-New Drug Application (NDA) for trilaciclib submitted in June 2020RESEARCH TRIANGLE PARK, N.C. and RIDGEFIELD, Conn., June 30, 2020 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (Nasdaq: GTHX) and Boehringer Ingelheim today announced that the companies have entered into a co-promotion agreement for trilaciclib in the United States and Puerto Rico. Under the terms of the three-year agreement, G1 and Boehringer Ingelheim will collaborate on the commercialization of trilaciclib for its first potential indication in small cell lung cancer (SCLC), with the Boehringer Ingelheim oncology commercial team, well-established in...

Continue reading

Stein Mart, Inc. Reports First Quarter 2020 Results and Provides Update on COVID-19 Response

First quarter net loss of $(65.7) million or $(1.38) per share compared to net income of $4.0 million or $0.08 per share in 2019Actions taken in response to COVID-19 to preserve liquidityAll stores re-opened by June 15 with reduced hoursJACKSONVILLE, Fla., June 30, 2020 (GLOBE NEWSWIRE) — Stein Mart, Inc. (NASDAQ: SMRT) today announced financial results for the first quarter ended May 2, 2020 and provided an update on its response to the COVID-19 pandemic. Results include $10.3 million of non-cash long-lived asset impairment charges which are preliminary and subject to adjustment.Covid-19 UpdateThe Company’s first quarter results were impacted by the temporary closure of all stores on March 19 due to the COVID-19 pandemic. Beginning April 23, the Company began the staggered reopening of stores. All stores were re-opened as of June...

Continue reading

T2 Biosystems Announces U.S. Launch of COVID-19 Diagnostic Test

LEXINGTON, Mass., June 30, 2020 (GLOBE NEWSWIRE) — T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced the completion of validation of its COVID-19 molecular diagnostic test, the T2SARS-CoV-2 Panel. The test was developed by T2 Biosystems under a license agreement with the Center of Discovery and Innovation at Hackensack Meridian Health and is being commercially distributed after validation meeting requirements for an Emergency Use Authorization (EUA) request to FDA. The T2SARS-CoV-2 Panel is designed to detect SARS-CoV-2, the virus that is responsible for COVID-19 infections. The T2SARS-CoV-2 Panel provides sample-to-answer results in less than two hours, utilizing a nasopharyngeal swab sample. Clinical testing on known positive and negative patient samples showed a sensitivity...

Continue reading

USI Insurance Services Completes Acquisition of Associated Benefits & Risk Consulting

VALHALLA, N.Y., June 30, 2020 (GLOBE NEWSWIRE) — USI Insurance Services (“USI”), a world leader in risk management, employee benefit and retirement plan consulting, today announced the completion of its acquisition of Associated Benefits & Risk Consulting (ABRC) from Associated Banc-Corp (NYSE: ASB). ABRC is a multi-line insurance agency and Midwest-based consulting firm with 400 employees, providing employee benefits, retirement plans, compliance, business insurance, risk management and individual insurance solutions.

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.